{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:26Z","timestamp":1791924206081,"version":"4.3.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>The emergence of bispecific antibodies for multiple myeloma presents a critical unanswered question for solid organ transplant recipients: Can these T-cell dependent therapies overcome concurrent immunosuppression without triggering graft rejection? While teclistamab and similar agents demonstrate remarkable efficacy in immunocompetent patients, their mechanism demands functional T-cells\u2014precisely what calcineurin inhibitors and antimetabolites suppress in transplant recipients. This creates a perilous therapeutic trilemma: (1) Maintaining standard immunosuppression risks blunting bispecific efficacy, (2) reducing immunosuppression may precipitate graft rejection, while (3) both strategies compound already elevated infection risks from dual immunosuppressive effects. Our experience treating two renal transplant recipients with teclistamab reveals these tensions in practice\u2014one patient achieved sustained response without rejection, while another faced infectious complications preceding disease progression. These cases highlight three urgent research priorities: prospective studies to define (a) minimum effective immunosuppression levels during bispecific therapy, (b) biomarkers predicting graft rejection risk, and (c) optimal infection prophylaxis strategies. Until such data exists, clinicians navigate this high-stakes balancing act without evidence, forced to weigh theoretical risks of allograft loss against known mortality from progressive myeloma.<\/jats:p>","DOI":"10.1177\/10815589251364807","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T03:43:14Z","timestamp":1753760594000},"page":"289-293","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Bispecific T-cell engagers for relapsed\/refractory multiple myeloma after solid organ transplantation: A case series"],"prefix":"10.1177","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4131-763X","authenticated-orcid":false,"given":"Raul","family":"Gregg-Garcia","sequence":"first","affiliation":[{"name":"Department of Medicine, Indiana University School of Medicine, Indianapolis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine. Indianapolis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-8781","authenticated-orcid":false,"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine. Indianapolis, USA"},{"name":"Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0057"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1527198"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47801-8"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1050522"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01793-1"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12234"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.11.024"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2018.01.014"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.05.018"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18828"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589251364807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589251364807","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589251364807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:40:33Z","timestamp":1777459233000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589251364807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1177\/10815589251364807"],"URL":"https:\/\/doi.org\/10.1177\/10815589251364807","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}